New Peer-Reviewed Publications Highlight Effectiveness of OMNI® Surgical System with TruSync™ Technology in Reducing IOP and Medication Usage in Cataract Combination Procedures, Standalone Procedures, and in African Americans

Core Insights - Sight Sciences, Inc. announced results from three key studies demonstrating the effectiveness of interventional treatments for glaucoma, emphasizing the importance of innovative surgical solutions in managing intraocular pressure (IOP) and reducing medication reliance [1][2][6] Group 1: Study Results - A 24-month prospective study showed that the standalone OMNI procedure reduced mean IOP from 26.1 mmHg to an average of 15.5 mmHg at 12 months and 15.5 mmHg at 24 months, with a significant reduction in medication use from 1.8 to 0.5 [6] - In a retrospective study involving nearly 13,000 African American eyes, the OMNI procedure demonstrated the highest proportion of patients achieving a greater than or equal to 20% reduction in IOP compared to other minimally invasive glaucoma surgeries [6] - A subgroup analysis of 220 eyes undergoing the standalone OMNI procedure indicated significant IOP reductions maintained for up to 3 years, regardless of lens status or disease severity [6] Group 2: Company Overview - Sight Sciences focuses on developing and commercializing innovative, interventional technologies aimed at transforming eye care and improving patient outcomes, particularly through minimally invasive approaches [8] - The company's OMNI and SION surgical systems are designed to reduce IOP in adult patients with primary open-angle glaucoma, addressing a leading cause of irreversible blindness globally [8] - The TearCare System is also part of the company's portfolio, targeting evaporative dry eye disease through localized heat therapy [8]